Sign Up Today and Learn More About Phagenesis Stock
Invest in or calculate the value of your shares in Phagenesis or other pre-IPO companies through EquityZen's platform.
Phagenesis Stock
Phagenesis is engaged in the development of a device to treat dysphagia, a condition that disables the safe swallowing of food.
About Phagenesis Stock
Founded
2007
Industries
Software, Artificial Intelligence, Data and Analytics
Phagenesis Press Mentions
Stay in the know about the latest news on Phagenesis
Phagenesis raises ÂŁ33m in Series D funding round
businesscloud • Mar 07, 2024
Phagenesis Secures $42M Investment Led by EQT Life Sciences to Revolutionize Swallowing Disorder Treatment
news • Mar 06, 2024
Phagenesis, a medical device company specializing in the treatment of swallowing disorders, successfully closes a $42M Series D financing round led by EQT Life Sciences and Sectoral Asset Management
prnewswire • Mar 04, 2024
Phagenesis raises $42m to take medical device for swallowing disorders to the US
sifted • Mar 04, 2024
Phagenesis Launches Phagenyx Neurostimulation System in the U.S.
prnewswire • Oct 12, 2022
Phagenesis Management
Leadership team at Phagenesis
Chief Executive Officer
Reinhard Krickl
Vice President Therapy Development
Scott Grant
Join now and verify your accreditation status to gain access to:
- Phagenesis current valuation
- Phagenesis stock price
- Available deals in Phagenesis and all other companies
- Deal offering documents
- EquityZen's proprietary data and insights, including
- Cap tables, which include funding history by Share Class and Liquidity Preferences
- Company Highlights
- Business Model
- Risk Factors
Trading Phagenesis Stock
How to invest in Phagenesis stock?
Accredited investors can buy pre-IPO stock in companies like Phagenesis through EquityZen funds. These investments are made available by existing Phagenesis shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.
How to sell Phagenesis stock?
Shareholders can sell their Phagenesis stock through EquityZen's private company marketplace. EquityZen's network includes over 330K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.
If I invest, how do I exit my investment?
There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.
Why choose EquityZen?
Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 43K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."
